NICE has recommended the reimbursement for tebentafusp in HLA-A*02:01–positive unresectable or metastatic uveal melanoma.
Publications
Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma
A biologics license application was submitted to the FDA seeking the accelerated approval of RP1 (vusolimogene oderparepvec) plus nivolumab (Opdivo) for the treatment of adult patients with advanced melanoma who have received prior treatment with a regimen containing a PD1 inhibitor. The combination also received breakthrough therapy designation from the FDA for the same designation.
National targeted skin cancer screening to be accelerated with $10.3 million investment
The Albanese Government is investing $10.3 million to tackle the most common cancer in our sunburnt country, skin cancer.
FDA Grants RMAT Designation to Novel TIL Therapy OBX-115 in Melanoma
This designation follows the fast track designation that was granted to OBX-115 for the same indication in July 2024.